Literature DB >> 26514677

Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.

Efstratios Koutroumpakis1, Claudia Ramos-Rivers2, Miguel Regueiro3, Jana G Hashash4, Arthur Barrie5, Jason Swoger6, Leonard Baidoo7, Marc Schwartz8, Michael A Dunn9, Ioannis E Koutroubakis10, David G Binion11.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) has been linked to an increased risk of coronary heart disease and stroke. Dyslipidemia is a well-established risk factor for cardiovascular disease. The aim of this study was to investigate the long-term lipid profiles in a large cohort of IBD patients.
METHODS: Data of patients from an IBD registry who had more than one measurement of total cholesterol and triglyceride levels during the follow-up period were analyzed. The lipid profiles of IBD patients were compared to those of the general population according to National Health and Nutrition Examination Survey (2009-2012). Quartiles of cholesterol or triglyceride levels in relation to surrogate markers of disease severity were analyzed.
RESULTS: Seven hundred and one IBD patients [54% Crohn's disease (CD), 46% ulcerative colitis (UC)] were included. IBD patients had less frequent high total cholesterol and high LDL cholesterol (6 vs. 13 and 5 vs. 10%) and more frequent low HDL and high triglycerides (24 vs. 17 and 33 vs. 25%) compared to the general population (all p < 0.001). Median total cholesterol levels were lower and median triglycerides higher in CD compared to UC (171 vs. 184; 123 vs. 100 mg/dL; both p < 0.001). In the multiple regression analysis, lipid profile was independently associated with hospitalizations (low cholesterol) and IBD surgeries (low cholesterol and high triglycerides).
CONCLUSIONS: Low total cholesterol and high triglyceride levels are more frequent in IBD patients (in particular CD) compared to healthy controls and are independently associated with more severe disease.

Entities:  

Keywords:  Cardiovascular risk; Cholesterol; Crohn’s disease; Triglycerides; Ulcerative colitis

Mesh:

Substances:

Year:  2015        PMID: 26514677     DOI: 10.1007/s10620-015-3932-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA.

Authors:  D S FREDRICKSON; R S LEES
Journal:  Circulation       Date:  1965-03       Impact factor: 29.690

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 3.  Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.

Authors:  Jamie Robertson; Mike J Peters; Iain B McInnes; Naveed Sattar
Journal:  Nat Rev Rheumatol       Date:  2013-06-18       Impact factor: 20.543

Review 4.  New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia.

Authors:  Bhavin B Adhyaru; Terry A Jacobson
Journal:  Cardiol Clin       Date:  2015-05       Impact factor: 2.213

5.  The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.

Authors:  Ioannis E Koutroubakis; Claudia Ramos-Rivers; Miguel Regueiro; Efstratios Koutroumpakis; Benjamin Click; Marc Schwartz; Jason Swoger; Leonard Baidoo; Jana G Hashash; Arthur Barrie; Michael A Dunn; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2015-07       Impact factor: 5.325

6.  Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias.

Authors:  Henry Buchwald; Kyle D Rudser; Stanley E Williams; Van N Michalek; James Vagasky; John E Connett
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

Review 7.  Epidemiology, risk factors and management of cardiovascular diseases in IBD.

Authors:  Siddharth Singh; Iftikhar J Kullo; Darrell S Pardi; Edward V Loftus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

8.  Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.

Authors:  Seth D Crockett; Richard A Hansen; Til Stürmer; Robin Schectman; Jane Darter; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2011-08-08       Impact factor: 5.325

9.  Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Pantelis Oustamanolakis; Niki Malliaraki; Konstantinos Karmiris; Ioannis Chalkiadakis; Emmanouel Ganotakis; Nikolaos Karkavitsas; Elias A Kouroumalis
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-03       Impact factor: 2.566

10.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Authors:  R A Kozarek; D J Patterson; M D Gelfand; V A Botoman; T J Ball; K R Wilske
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

View more
  12 in total

1.  Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia and in vitro Hepatic Lipogenic-Related Gene Expression: A Population-Based Cohort Study.

Authors:  Ni Tien; Tien-Yuan Wu; Cheng-Li Lin; Chia-Jui Wu; Chung-Y Hsu; Yi-Jen Fang; Yun-Ping Lim
Journal:  Front Med (Lausanne)       Date:  2022-06-13

2.  Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease.

Authors:  Alejandro Hernández-Camba; Marta Carrillo-Palau; Laura Ramos; Laura de Armas-Rillo; Milagros Vela; Laura Arranz; Miguel Á González-Gay; Iván Ferraz-Amaro
Journal:  Clin Transl Gastroenterol       Date:  2022-06-01       Impact factor: 4.396

3.  Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.

Authors:  Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

4.  Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn's Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling.

Authors:  Elizabeth A Scoville; Margaret M Allaman; Caroline T Brown; Amy K Motley; Sara N Horst; Christopher S Williams; Tatsuki Koyama; Zhiguo Zhao; Dawn W Adams; Dawn B Beaulieu; David A Schwartz; Keith T Wilson; Lori A Coburn
Journal:  Metabolomics       Date:  2017-12-29       Impact factor: 4.290

5.  Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients.

Authors:  Ryuji Morishige; Hiroshi Nakajima; Kazutake Yoshizawa; Jörg Mahlich; Rosarin Sruamsiri
Journal:  Adv Ther       Date:  2016-11-02       Impact factor: 3.845

6.  The potential of metabolic and lipid profiling in inflammatory bowel diseases: A pilot study.

Authors:  Cristian Tefas; Lidia Ciobanu; Marcel Tanțău; Corina Moraru; Carmen Socaciu
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

7.  Correlation of Paraoxonase-1 with the Severity of Crohn's Disease.

Authors:  Katarzyna Szczeklik; Tomasz Mach; Dorota Cibor; Danuta Owczarek; Jacek Sapa; Monika Papież; Jolanta Pytko-Polończyk; Wirginia Krzyściak
Journal:  Molecules       Date:  2018-10-11       Impact factor: 4.411

8.  Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD.

Authors:  Elleni J Pippis; Bruce R Yacyshyn
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 5.325

9.  Hypocholesterolemia and Inflammatory Biomarkers Act as Predictors of Severe Vitamin D Deficiency in Patients With Crohn's Disease: A Clinical Analysis of 862 Patients in China.

Authors:  Jie Lu; Fei Yu; Jun Huang; Haitao Yu; Fengying Li; Zhi'an Le; Yulan Cheng; Qi Zhang; Guiling Li; Xinyou Xie; Huifang Tang; Jun Zhang
Journal:  Front Nutr       Date:  2022-04-13

10.  Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis.

Authors:  Fay Probert; Alissa Walsh; Marta Jagielowicz; Tianrong Yeo; Timothy D W Claridge; Alison Simmons; Simon Travis; Daniel C Anthony
Journal:  J Crohns Colitis       Date:  2018-11-15       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.